Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
Aspira Women's Health Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Aspira Women's Health Inc 주요 수익원은 Bio-analytic and Diagnostic Services이며, 최신 수익 발표에서 수익은 9,154,000입니다. 지역별로는 United States이 Aspira Women's Health Inc의 주요 시장이며, 수익은 9,154,000입니다.
Aspira Women's Health Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Aspira Women's Health Inc의 순손실은 $-13입니다.